LEADING PRODUCT CANDIDATE
SymphonyTM
Bluejay Diagnostics is pleased to present Symphony, a near-patient biomarker detection platform. Symphony aims to help improve healthcare outcomes by providing quantitative clinical chemistry results vital for triage and acute care..
Symphony is an innovative implementation of the traditionally reliable ELISA methodology combined with modern advances in nanotechnology. The unique design features a combination of microfluidics and interrupted fluid dynamics to offer fast, simple, safe, and highly sensitive biomarker detection.
*Not FDA cleared. For research use only


WHO WE ARE
Bluejay Diagnostics is focused on improving patient outcomes through a more cost efficient, rapid, near patient product for triage, diagnosis, and monitoring of disease progression.

PRODUCTS IN DEVELOPMENT
Symphony is an automated diagnostic system, consisting of a fluorescence immuno-analyzer which uses a single-use diagnostic test cartridge with reagents integrated in the cartridge. Symphony utilizes a ‘sample-to-result’ format, which means that once a specimen is taken from the patient, it is placed in the cartridge and then the cartridge is placed inside the analyzer where the test is run without further technician intervention or additional reagent. This reduces test complexity and eliminates the need for highly trained and expensive laboratory technicians to run the tests.
Our platform is designed to enable simple, rapid, and cost-effective analysis from a single clinical sample, which will allow LTACs, hospitals and clinics that traditionally could not afford more expensive or complex diagnostic testing platforms to modernize their laboratory testing and provide better patient testing at an affordable cost in time sensitive, life threatening situations.
LATEST NEWS
Highlights

Bluejay Diagnostics Provides Mid-Year Business and Corporate Update
ACTON, Mass. , June 03, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update.

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting
ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025.

Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds
ACTON, Mass. , April 07, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics , Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered.
OUR TEAM
Meet the Bluejays

Neil Dey

Diane Palermo

Amit K. Roy

Lekha Papammagari

Tina McCarthy
OUR TEAM
Meet the Management Team

Neil Dey

Diane Palermo

Amit K. Roy

Lekha Papammagari
